Prostate cancer

Launched in 2012, the Michigan Urological Surgery Improvement Collaborative works to improve the quality of care for men with prostate cancer.  Urologists statewide review data including cancer severity, utilization and care patterns for various cancer therapies and treatments.

By comparing data and sharing observations, participants can identify best practices associated with improved patient outcomes, as well as share these best practices with other physicians throughout Michigan.  Objectives include reducing complications from biopsy, improving outcomes after prostatectomy, and reducing variation.

For more information, go to


  • Collected data on more than 24,000 patients in 3.5 years of data collection.
  • Participants include 235 urologists, representing 42 practices.
  • Partnered with four patient advocates, as well as the spouse of a patient.  These individuals are involved in all of the consortium’s activities and offer the patient perspective, which is critical to the program’s success.
  • Approved by CMS as a PQRS Qualified Clinical Data Registry (QCDR).
  • By using comparative performance feedback, review of current guidelines, and dissemination of best practices, achieved a statewide decrease in the use of both bone scans and CT scans for men with low-risk prostate cancer.
  • Used MUSIC data to develop and implement evidence-based appropriateness criteria for radiographic staging of all men with newly-diagnosed prostate cancer.
  • Achieved a 50 percent reduction in prostate biopsy-related hospitalizations by implementing process changes for antibiotic prophylaxis focused on addressing fluoroquinolone resistance.
  • Established a novel metric (MUSIC NOTES) that defines an uncomplicated early post-operative recovery, and compares these outcomes across diverse urology practices.
  • Created a statewide, electronic infrastructure for measuring and improving patient-reported functional outcomes after radical prostatectomy.
  • Developed an infrastructure for video-based assessment of surgical technique with the aim of linking such assessments with patient-reported outcomes data, thereby allowing examination of the extent to which differences in technical proficiency can be distinguished, and whether they matter, for patients undergoing robotic prostatectomy.
  • Developed appropriateness criteria and a standardized framework for recommending treatment for patients with low-risk prostate cancers.  This tool can be combined with the assessment of patient preferences to facilitate shared decision making.
  • Published 11 peer-reviewed manuscripts, as well as more than 20 abstracts, and gave more than 40 presentations on MUSIC’s work and QI successes at both a national and international level.
  • Winner of the inaugural Clinical Innovator Technology (CIT) Accelerator Award.
  • Awarded the Blue Cross Blue Shield Association Best of Blue award for clinical distinction for the MUSIC program.